These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25358029)

  • 1. A statistical approach to determining criticality of residual host cell DNA.
    Yang H; Wei Z; Schenerman M
    J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
    Tsong Y; Yang H
    J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical procedure validation and the quality by design paradigm.
    Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
    J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
    Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
    J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing assay linearity over a pre-specified range.
    Yang H; Novick SJ; LeBlond D
    J Biopharm Stat; 2015; 25(2):339-50. PubMed ID: 25356663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A direct qPCR method for residual DNA quantification in monoclonal antibody drugs produced in CHO cells.
    Hussain M
    J Pharm Biomed Anal; 2015 Nov; 115():603-6. PubMed ID: 25850374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
    Fan Z; Zhang L
    J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization and validation of DNA extraction and real-time PCR assay for the quantitative measurement of residual host cell DNA in biopharmaceutical products.
    Hu B; Sellers J; Kupec J; Ngo W; Fenton S; Yang TY; Grebanier A
    J Pharm Biomed Anal; 2014 Jan; 88():92-5. PubMed ID: 24042121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A probabilistic model for risk assessment of residual host cell DNA in biological products.
    Yang H; Zhang L; Galinski M
    Vaccine; 2010 Apr; 28(19):3308-11. PubMed ID: 20226252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal real-time PCR assay for quantitation and size evaluation of residual cell DNA in human viral vaccines.
    André M; Reghin S; Boussard E; Lempereur L; Maisonneuve S
    Biologicals; 2016 May; 44(3):139-49. PubMed ID: 27033773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific detection of residual CHO host cell DNA by real-time PCR.
    Nissom PM
    Biologicals; 2007 Jun; 35(3):211-5. PubMed ID: 17071102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing history of etanercept (Enbrel
    Hassett B; Singh E; Mahgoub E; O'Brien J; Vicik SM; Fitzpatrick B
    MAbs; 2018 Jan; 10(1):159-165. PubMed ID: 29020515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment of Madin Darby canine kidney cells as vaccine substrate.
    Medema JK; Meijer J; Kersten AJ; Horton R
    Dev Biol (Basel); 2006; 123():243-50; discussion 265-6. PubMed ID: 16566450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.